Covid-19 and immunomodulation in IBD. Neurath MF, 2020. Gut; 0:1–8.

The world is currently facing a coronavirus pandemic (SARS-CoV-2) that has led to a health crisis in many cases. The disease caused by this virus, COVID-19, may produce severe complications such as pneumonia or organ failure driven by hyperinflammation. This situation implies major challenges for IBD treatment in these days. It’s not yet understood whether patients with this condition are particularly susceptible to COVID-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. In addition, several IBD treatments work through immunosuppression or immunomodulation, affecting the progress of this viral disease. 

In this review, the current understanding of the pathophysiology of COVID-19 is analysed, with special detail on immune cell activation. Moreover, the publication discusses the potential implications of this new knowledge for immunomodulation and biological therapy in IBD.

 

Management of IBD During the COVID-19 Outbreak: Resetting Clinical Priorities. Danese S., Cecconi M. and Spinelli A. 2020. Nat Rev Gastroenterol Hepatol. May;17(5):253-255.

The COVID-19 outbreak has been a fast and evolving situation during the last months which has become a public health emergency of international concern. This disease may have specific implications for people enduring previous medical conditions such as IBD. Patients with these diseases may wonder if they have an increased risk of infection and may ask practitioners about what precautions to take, particularly those patients under immunosuppressive treatment. Healthcare professionals specialised in IBD may be asked for counselling on this matter without having accurate answers available. 

In this article, the authors describe the clinical issues that IBD specialists could face during the COVID-19 pandemic. They have highlighted the potential rearrangements of care and the clinical priorities, and they have reviewed the information available to answer potential questions that IBD patients may have.